SCYNEXIS
David Angulo is currently the Chief Executive Officer and Chief Medical Officer at SCYNEXIS, a biotechnology company focused on developing innovative anti-infective therapies. David previously held positions at Brickell Biotech, Inc. as Vice President, Research and Development, and at Stiefel as Vice President, Clinical Research. Before that, David worked at Schering-Plough as an Executive Director in Global Clinical Research. David holds a MD in Infectious Diseases from the Universidad Nacional Autónoma de México.
SCYNEXIS
2 followers
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant fungal infections.